Dabigatran is an oral, reversible thrombin inhibitor that has shown promising results in large
clinical trials. Laboratory monitoring is not needed but the effects on common coagulation …

Background Knowledge of anticoagulation status during dabigatran therapy may be
desirable in certain clinical situations. Objective To determine the coagulation tests that are …

Background: Patients receiving the direct thrombin inhibitor dabigatran may have selected
anticoagulation assays performed as part of routine care. The effect of dabigatran on the …

Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …

Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU
and several other countries for the prevention of venous thromboembolism after elective hip …

INTRODUCTION: The new oral anticoagulants are effective alternatives for warfarin but
specific antidotes are not yet available for these agents to manage life-threatening bleeding …

The objective of the present study was to assess the suitability of an accurate, sensitive,
standardized, chronometric blood coagulation test to determine the anticoagulation activity …

Due to low bioavailability and high inter-individual variability, monitoring of dabigatran may
be required in specific situations to prevent the risk of bleedings or thrombosis. The aim of …

The oral direct thrombin inhibitor dabigatran effectively prevents arterial and venous
thromboembolism using fixed doses without the need for adjustment according to laboratory …

Aims The novel direct thrombin inhibitor (DTI), dabigatran etexilate (Boehringer Ingelheim
Pharma GmbH & Co. KG), shows potential as an oral antithrombotic agent. Two double …